Browse by Hotbed/Location
Filter News
Found 621,505 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
-
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.
-
The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.
-
The product is designed to help heal patients who have received thermal burns that would ultimately require a skin graft.
-
In an eight page letter to U.S. DOH and Human Services Secretary Xavier Becerra, Public Citizen said Woodcock and other FDA officials should resign.
-
The new data shows REGEN-COV reduced the risk of death in hospitalized patients unable to mount their own immune response by 20%.
-
Repurposed drugs became the front-line defense against COVID-19 within a few months of the pandemic’s emergence. Now bucillamine, currently in Phase III trials in the U.S., may be poised to join them.
-
The company’s lead candidate, INNA-051, is an innate immune agonist that directly stimulates the host’s natural immune defense system.
-
Money on the Move: June 9-15
6/16/2021
Each week more money pours into the biopharma world. Here's a peek at who's getting a taste of fresh funds this week. -
Both MannKind and United Therapeutics entered into a global and exclusive licensing and collaboration agreement to develop and commercialize Tyvaso DPI.
-
This week, the German drug company announced that it is closing the doors to its 'innovation hub' in Mission Bay.
-
Starton Therapeutics Phase 2 TROPIC-I Clinical Study will be First to Use Total Control Primary Endpoint in Superiority StudySTAR-OLZ for acute and delayed chemotherapy induced nausea and vomiting (CINV)
6/16/2021
Starton Therapeutics Inc. announces Type C Meeting Responses from the US Food and Drug Administration (FDA) leading to the finalization of the Company's clinical development approach for STAR-OLZ in Chemotherapy Induced Nausea and Vomiting (CINV).
-
Abstract Published in Neuro-Oncology Demonstrates Curtana Pharmaceuticals’ CT-179 Prolonged Event-free Survival in an Animal Model of Medulloblastoma
6/16/2021
Data Presented in Oral Presentation at the SNO 6th Biennial Pediatric Neuro-Oncology Research Conference.
-
KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension
6/16/2021
KBP Biosciences today announced publication of the results of the BLOCK-CKD (Blood Pressure in Chronic Kidney Disease) phase 2b study of KBP-5074.
-
VistaGen Therapeutics Set to Join the Russell 2000® Index
6/16/2021
VistaGen Therapeutics, Inc today announced the Company will be added to the Russell 2000® Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective June 28, 2021.
-
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)
6/16/2021
Neurona today announced the presentation of clinical trial plans and supporting preclinical data for its lead inhibitory neuron cell therapy candidate, NRTX-1001.
-
Apexigen and the Nordic Society of Gynaecological Oncology – Clinical Trial Unit Announce Collaborative Phase 2 Study of Sotigalimab (APX005M)
6/16/2021
Apexigen, Inc. today announced an agreement to initiate a collaborative Phase 2 clinical study evaluating sotigalimab,
-
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
6/16/2021
BeyondSpring today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent corporate events.
-
Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist
6/16/2021
Gannex today announces positive topline results of safety and pharmacodynamic biomarkers from the U.S. Phase I trial of NASH drug farnesoid X receptor (FXR) agonist ASC42.